Skip to main content
. Author manuscript; available in PMC: 2016 Mar 11.
Published in final edited form as: Clin Auton Res. 2015 Mar 11;25(1):53–59. doi: 10.1007/s10286-015-0271-4

Figure 5.

Figure 5

Panel A. Systolic blood pressure measurements (y-axis) with 18 mg of atomoxetine and placebo in patients with central autonomic failure or MSA. SBP increased significantly with atomoxetine 18 mg (P=<0.001); the asterisk (*) indicates P=<0.001.

Panel B. Systolic blood pressure measurements with atomoxetine and placebo in patients with peripheral autonomic failure (PAF, PD+). No significant changes in SBP were observed (P=0.08).